This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Zacks Market Edge Highlights: MJ, YOLO, THCX, TLRY and CRON
by Zacks Equity Research
Zacks Market Edge Highlights: MJ, YOLO, THCX, TLRY and CRON
Should You Buy a Cannabis ETF?
by Tracey Ryniec
There are now 3 pot ETFs with several more to launch soon. Is this a good way for investors to get exposure to the cannabis industry?
What to Make of Constellation Brands (STZ) Stock Heading into Q1 Earnings
by Mitchell Moore
Constellation Brands Inc (STZ), a leading producer and marketer of alcoholic beverage brands, is expected to release its Q1 fiscal 2020 earnings results before the bell this Friday, June 28. Our Zacks Consensus Estimate calls for quarterly EPS of $2.07.
Implied Volatility Surging for Tilray (TLRY) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Tilray (TLRY) stock based on the movements in the options market lately.
Canopy Growth Earnings After Bell 6/20: Key Word Growth
by Daniel Laboe
CGC analysts are estimating an EPS of -0.17 and revenues of $71 million. Shareholders are voting today on whether to acquire Acreage Holdings, which could propel CGC one way or the other.
Beverages - Alcohol Industry Trends Suggest Growth in the Future
by Rajani Lohia
The alcohol space looks poised for growth as premium and innovative beverages are gaining traction. Meanwhile, cannabis drinks provide a lucrative opportunity for growth.
Marijuana Stocks & ETFs: What Investors Need to Know
by Neena Mishra
Here is what investors need to know about cannabis investing and the first actively managed pot ETF.
The Cannabis Craze
by Daniel Laboe
The "Cannabis Craze" had everyone and their brother buying up marijuana stocks. These cannabis stocks didn't have enough free-floating shares to cover the massive amount of buy interest leading them to skyrocketed at the end of 2018 far above their fair value.
Company News For May 16, 2019
by Zacks Equity Research
Companies in the news are: M, BABA, TLRY and XLNX
Are Options Traders Betting on a Big Move in Tilray (TLRY) Stock?
by Zacks Equity Research
Investors need to pay close attention to Tilray (TLRY) stock based on the movements in the options market lately.
Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on pipeline progress and updates, when Tilray (TLRY) reports first-quarter 2019 results.
Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on pipeline progress and updates, when Tilray (TLRY) reports first-quarter 2019 results.
Marijuana ETFs Head-to-Head
by Neena Mishra
Here is what investors need to know about cannabis investing and the two ETFs that provide exposure to the space.
The Zacks Analyst Blog Highlights: Scott's Miracle Grow, GW Pharmaceuticals, Canopy Growth, Tilray and Aurora Cannabis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Scott's Miracle Grow, GW Pharmaceuticals, Canopy Growth, Tilray and Aurora Cannabis
Tilray, Inc. (TLRY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Tilray, Inc. (TLRY) closed at $46.40 in the latest trading session, marking a +0.76% move from the prior day.
Buy Marijuana Stocks, Tilray & Aurora Cannabis, Before Earnings?
by Benjamin Rains
The legal marijuana industry is still in the early stages, so let's see if investors should consider buying some pure-play marijuana stocks heading into earnings.
5 Pot Stock Earnings Charts
by Tracey Ryniec
It's an emerging industry, but are companies actually beating on earnings?
Tilray, Inc. (TLRY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Tilray, Inc. (TLRY) closed at $51.95, marking a +1.21% move from the previous day.
Zacks Value Trader Highlights: Novavax, J.C. Penney, Pier 1 Imports, Tilray and Aurora Cannabis
by Zacks Equity Research
Zacks Value Trader Highlights: Novavax, J.C. Penney, Pier 1 Imports, Tilray and Aurora Cannabis
Tilray, Inc. (TLRY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Tilray, Inc. (TLRY) closed at $51.26 in the latest trading session, marking a +1.99% move from the prior day.
Should You Buy Lottery Stocks?
by Tracey Ryniec
Like playing the lottery, some stocks lure in investors with the promise of possible riches.
Zacks Investment Ideas feature highlights: Canopy Growth, Tilray and Constellation Brands
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Canopy Growth, Tilray and Constellation Brands
Likely Canopy-Acreage Deal Looks Good Enough to Boost ETF MJ
by Sanghamitra Saha
Canopy Growth will probably purchase the rights to buy Acreage Holdings to tap the growing potential of the U.S. marijuana market. This should bolster the ETF MJ.
Options Traders Expect Huge Moves in Tilray (TLRY) Stock
by Zacks Equity Research
Tilray (TLRY) needs investors to pay close attention to the stock based on moves in the options market lately.
The Zacks Analyst Blog Highlights: Constellation Brand, Canopy Growth, Aurora Cannabis, Cronos and Tilray
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Constellation Brand, Canopy Growth, Aurora Cannabis, Cronos and Tilray